Benzinga | Apr 30, 2021 04:05PM EDT

Progenity Highlights Presentation Of Key Verification Study Data For Preecludia At 2021 American College Of Obstetricians And Gynecologists Annual Meeting

Progenity, Inc. (NASDAQ:PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced new data from its Preecludia preeclampsia rule-out test verification study are being presented today at the 2021 ACOG Annual Meeting, with the test demonstrating sensitivity of 87.8% and a negative predictive value (NPV) of 97.0%. The company recently announced it is in the clinical validation testing phase of Preecludia, with a targeted launch expected in the second half of 2021.